the highest among the EU4 and the UK. .Chemotherapy-induced diarrhea, particularly Grade III-IV, can lead to dose reductions, treatment delays, or even discontinuation in up to 70% of patients ...

According to estimates Grade I–II chemotherapy-related diarrhea accounted for nearly 60,000 new cases in Germany in 2023, the highest among the EU4 and the UK. • Chemotherapy-induced diarrhea ...

According to estimates Grade I–II chemotherapy-related diarrhea accounted for nearly 60,000 new cases in Germany in 2023, the highest among the EU4 and the UK. • Chemotherapy-induced diarrhea, ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell ...

The median duration of chemotherapy infusion and intravenous hydration were 5.79 and 27.58 hours with SH and CH, respectively. A total of 32.8% and 33.3% of the SH and CH groups, respectively, ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Perioperative chemotherapy ... group. Grade 3 or higher adverse events with an incidence of 5% or more in at least one of the trial groups were neutropenia (in 19.8% of the patients), diarrhea ...

Previous results from this study showed that zenocutuzumab induced fast and ... The most common grade 3 or 4 treatment-related adverse events were diarrhea and anemia, occurring in three patients ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Methods: The clinical data of patients with different indications receiving 1-3 courses of WMT were retrospectively ... 4.64%), gouty arthritis (n=7, 2.95%), chemotherapy-related diarrhea (n=7, 2.95%) ...